Real estate company unveils plans for 45-acre biomanufacturing campus in Northeast Houston

life science upgrade

Generation Park has announced additional biomanufacturing facility development. Rendering courtesy of McCord

A Houston-based real estate company has reveals its plans to create a 45-acre biomanufacturing campus in the first phase of a life science development in Generation Park.

McCord Development released its plans for BioHub Two this week. The project will include 500,000 square feet for manufacturing, lab, and office space located in Generation Park, a 4,300-acre master-planned development in Northeast Houston.

The news of the BioHub follows Generation Park's December announcement of the San Jacinto College’s Biotech Training Center, a project in partnership with the National Institute of Biotechnology Research and Training. The institute will have a "bioprocessing pilot plant operated in a realistic GMP simulated and operational manufacturing environment," according to a news release from McCord.

“Houston has consistently been ranked as a burgeoning life science cluster, and BioHub Two has the unique advantage of being a short walk from the region’s only Biotech Training Center at San Jacinto College’s Generation Park campus," says John Flournoy, senior director of sales and leasing.

Last year, the Greater Houston Partnership released data showing the potential for the Bayou City as a hub for biomanufacturing, cell and gene therapy, cancer treatment, drug development, and more. Earlier this summer, Houston maintained its standing as a hub for life sciences on an annual report from CBRE.

“Houston’s high concentration of life sciences employment, healthy funding landscape, access to the Texas’ $6 billion CPRIT grant fund, and commitment to translational research is making it one of the country’s fastest growing life science ecosystems,” says Ryan McCord, president of McCord Development, in the release. “BioHub Two’s location in Generation Park is strategic and cost-effective, as the world-leading research and development facilities at the Texas Medical Center, Houston International Airport and Port of Houston are in close proximity.”

The larger Generation Part plans include two multifamily complexes, a mixed-use development called The Commons, and retail and green spaces.

The Texas Medical Center unveiled its plans for the TMC BioPort, a biomanufacturing and medical supplies distribution engine, almost a year ago. This new campus will span several hundred acres just down the road from TMC and will drive the much-needed repatriation of critical medical supplies and new cell and gene therapies, per a news release.

From Your Site Articles
This week's roundup of Houston innovators includes Armand Paradis of ComboCurve, Matthew Nojoomi of Ictero Medical, and Ryan McCord of McCord Development. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health tech to energy software — recently making headlines in Houston innovation.

Armand Paradis, co-founder of ComboCurve

Armand Paradis joins the Houston Innovators Podcast to discuss how his energy software business is scaling rapidly. Photo courtesy

Houston-based ComboCurve is growing rapidly. The energy software company has raised over $60 million in venture capital investment — $50 million of which was closed in the company’s series B round earlier this year. Since the original product launched in May of 2020, CEO and Co-Founder Armand Paradis says the platform has almost 200 companies on it.

“We built something that resonated with the market — and we were super passionate about the product and taking care of our industry,” Paradis says on the Houston Innovators Podcast. “We don’t want to be the best in oil and gas. We want to be the best software company." Click here to read more.

Matthew Nojoomi, CEO and co-founder of Ictero Medical

This innovative medical device company has closed $6 million for further product development and clinical trials. Image via TMC.edu

Houston-based medical device company Ictero Medical closed its oversubscribed series A at $6 million. The funding round was led by MedTex Ventures, S3 Ventures, and an undisclosed strategic investor. The company's novel cryoablation system was designed to treat high-risk gallstone disease patients and provide a less invasive and lower risk alternative to gallbladder removal surgery — something over 1 million Americans undergo annually.

“Our technology provides an immediate solution for critically ill patients who currently have no good treatment options, and also has the potential to benefit healthier patients who want to avoid surgery,” says Ictero Co-Founder and CEO Matthew Nojoomi in the release. Click here to read more.

Ryan McCord, president of McCord Development

Houston real estate expert shares why he thinks the city is prime for smart city tech and implementation. Photo courtesy

Houston has every tool in its toolkit to be able to emerge as a smart city leader. In a guest column for InnovationMap, Ryan McCord of McCord Development explains the momentum the city already has and the existing smart city opportunities already in town.

"Houston’s diversity, business-friendly environment, and workforce make it a prime candidate to become a smart city. Becoming smarter in our transportation, public safety, sustainability practices, and infrastructure will create a better future for Houstonians." Click here to read more.

Houston real estate expert shares why he thinks the city is prime for smart city tech and implementation. Photo via Getty Images

Houston has what it takes to emerge as a smart city leader, expert says

Guest column

While Houston has long been known as the Energy Capital of the World, there’s no reason we, as a city, cannot hold more than one title. What if Houston could take on the title of Smartest City in the World?

There are many factors that create a smart city, and it is deeper than just implementing new smart technology – it is a city that better supports the lifestyles of its residents seamlessly and unobtrusively. To effectively understand what the needs of the community are and the right types of technologies to implement when urban planning, data collection and data security measures are vital.

The City of Houston has already begun to use data and emerging technology to improve the quality of life for citizens, share information with the public, drive economic growth, and build a more inclusive society. To be successful and provide enriching experiences for Houstonians, these updates must happen at the infrastructure level, working as an integrated system that can be continuously optimized.

In 2015, Houston adopted an Open Data policy to support data sharing efforts between the government, its citizens, businesses and researchers. In addition to this, our city has made strategic investments in artificial intelligence, the Cloud, the Edge, smart sensors, big data, and more. These investments are being bolstered by private companies and institutions, building on these technologies to tackle urban problems, identify better solutions and enact privacy protections. These companies, such as McCord, are helping execute the city’s vision around development, transportation, public safety and community engagement.

Houston already has a case study

Citizens also play an active role in building the future of Houston through their behaviors and consumption patterns.

Take Generation Park, one of the largest privately held commercial developments in the country, sitting on 4,200 contiguous acres in Northeast Houston. As this land continues to be built out, developers at McCord partnered with Bosch technologies to implement sensors and other smart technologies to better understand how visitors are utilizing the trails, parking and space. These insights will then help McCord recognize parking patterns or which areas of the trails are most heavily trafficked, allowing the company to make more informed decisions regarding maintenance and infrastructure updates, ultimately providing a better experience for their visitors.

The data can also be factored in when planning events for the community. McCord will be able to use the data collected to determine things like the optimal times, preferred days and the need for parking at Redemption Square.

But the data use doesn’t stop at just events - tenants can use it to determine when to expect the dinner rush and apply that to staffing, prepping, happy hour specials and ultimately, factor it into better servicing their customers. Those living at Redemption Square’s 255 Assay Luxury Apartments will also benefit as McCord uses data trends to optimize their curbside management practices to better accommodate rideshare and food delivery services.

The plans for Redemption Square and Generation Park continue to adapt as data is collected and visitor behavior better understood. The goal of this data collection is to make Generation Park a citizen-optimized environment via cutting-edge technology where residents, visitors, employees, and businesses will thrive while knowing that their privacy is not at risk.

The bottom line

Houston’s diversity, business-friendly environment, and workforce make it a prime candidate to become a smart city. Becoming smarter in our transportation, public safety, sustainability practices, and infrastructure will create a better future for Houstonians.

Creating secure, holistic systems that work and learn together is central to successful smart city infrastructure. Private and public organizations must work together to collect data, pivot plans when needed and implement the correct technologies to ensure that these efforts ultimately make Houston a better place to live.

------

Ryan McCord is president of Houston-based McCord Development.

A new executive hire for McCord is going to focus on bringing smart city technology to Generation Park. Rendering courtesy of McCord

East Houston development launches smart city initiative with new hire

smart city

A 4,200-acre master-planned development that's rising on the east side of town has created a new role within their executive suite to drive innovation and a new smart city initiative.

Houston-based real estate developer, McCord, has hired Nick Cardwell as vice president of digital innovation. In the newly created role, Cardwell will be tasked with bringing data-driven solutions, digital transformation, and other smart city innovation to Generation Park.

"Sensor technology, machine learning, and big data capabilities have exploded in the last decade and are rapidly outpacing the built world," says Ryan McCord, president of McCord, in a press release. "Bolting this digital future onto aging cities is no easy task. With Generation Park, we have a once-in-a-lifetime opportunity to start from the beginning and rapidly prove up hardware and software technology solutions, at a massive scale."

Both the size of the development — which is larger than Google's Sidewalk Labs project in Canada and Toyota's Woven City in Japan, according to the release — and location are what provides Generation Park with this opportunity for smart city technology.

"Generation Park, while being physically many times larger than most smart city projects, also benefits from being located in a more physically, socially, and economically diverse test bed of a notoriously low-regulation part of the United States — Houston, Texas," McCord continues.

As the development is currently still being worked on, McCord's current focus right now is tapping into data to drive project and design decisions.

Cardwell has a background in technology and was previously overseeing operations and engineering at Austin-based construction software company, Bractlet.

"McCord's vision for Generation Park is the future of commercial development, pushing digital innovation into the forefront and leveraging cutting-edge technologies throughout their portfolio. I am beyond thrilled to join the McCord team and help make that vision a reality," says Cardwell, in the release. "Through the use of experiences, data, and collaborations, we will accelerate learnings and, in turn, advance resources that will truly improve people's lives."

Nick Cardwell has been hired as vice president of digital innovation at McCord. Photo courtesy of McCord

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings